Surface glycan targeting for cancer nano-immunotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Yonghyun | - |
dc.contributor.author | Kim, Jiwon | - |
dc.contributor.author | Chae, Jayoung | - |
dc.contributor.author | Hong, Joohye | - |
dc.contributor.author | Park, Jongjun | - |
dc.contributor.author | Jeong, Eunseo | - |
dc.contributor.author | Kim, Hayoung | - |
dc.contributor.author | Tanaka, Masayoshi | - |
dc.contributor.author | Okochi, Mina | - |
dc.contributor.author | Choi, Jonghoon | - |
dc.date.accessioned | 2022-02-08T08:40:56Z | - |
dc.date.available | 2022-02-08T08:40:56Z | - |
dc.date.issued | 2022-02 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.issn | 1873-4995 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/54922 | - |
dc.description.abstract | Cancer immunotherapy is an emerging therapeutic strategy for cancer treatment. Most of the immunotherapeutics approved by the FDA regulate the innate immune system and associated immune cell activity, with immune check inhibitors in particular having transformed the field of cancer immunotherapy due to their significant clinical potential. However, previously reported immunotherapeutics have exhibited undesirable side effects, including autoimmune toxicity and inflammation. Controlling these deleterious responses and designing therapeutics that can precisely target specific regions are thus crucial to improving the efficacy of cancer immunotherapies. Recent studies have reported that cancer cells employ glycan−immune checkpoint interactions to modulate immune cell activity. Thus, the recognition of cancer glycan moieties such as sialoglycans may improve the anticancer activity of immune cells. In this review, we discuss recent advances in cancer immunotherapies involving glycans and glycan-targeting technologies based on nanomaterial-assisted local delivery systems. © 2022 Elsevier B.V. | - |
dc.format.extent | 16 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier B.V. | - |
dc.title | Surface glycan targeting for cancer nano-immunotherapy | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jconrel.2022.01.004 | - |
dc.identifier.bibliographicCitation | Journal of Controlled Release, v.342, pp 321 - 336 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000745672700002 | - |
dc.identifier.scopusid | 2-s2.0-85123033022 | - |
dc.citation.endPage | 336 | - |
dc.citation.startPage | 321 | - |
dc.citation.title | Journal of Controlled Release | - |
dc.citation.volume | 342 | - |
dc.type.docType | Article | - |
dc.publisher.location | 네델란드 | - |
dc.subject.keywordAuthor | Cancer glycan | - |
dc.subject.keywordAuthor | Cancer immunotherapy | - |
dc.subject.keywordAuthor | Glycan targeting | - |
dc.subject.keywordAuthor | Glycosylation | - |
dc.subject.keywordAuthor | Nanoparticle | - |
dc.subject.keywordPlus | SIALIC-ACID | - |
dc.subject.keywordPlus | PROTEIN GLYCOSYLATION | - |
dc.subject.keywordPlus | DENDRITIC CELLS | - |
dc.subject.keywordPlus | TUMOR-GROWTH | - |
dc.subject.keywordPlus | FUCOSYLATION | - |
dc.subject.keywordPlus | NANOPARTICLES | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | RECEPTORS | - |
dc.subject.keywordPlus | BINDING | - |
dc.subject.keywordPlus | LEWIS | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.